




The Critical Need for New Antibiotics

There are not enough antibiotics in development globally to meet current and anticipated patient needs.

There are only **48 antibiotics** in clinical development.*



* Total number of antibiotics in phases 1-3 do not add up to 48 because one drug has completed phase 3 and its new drug application is currently under consideration by the Food and Drug Administration, and two drugs were approved.

Historical data show that, generally, only


1 in 5

infectious disease drugs that enter phase 1 trials will receive FDA approval.¹



Products can fail to receive approval for many reasons, including lack of effectiveness or safety concerns.

Antibiotics in Clinical Development With the Potential to Treat Infections Caused by Resistant Gram-Negative ESKAPE Pathogens[†]



There is a critical need for new **therapies** to treat deadly infections caused by Gram-negative ESKAPE pathogens²—bacteria that are often resistant to available antibiotics. **Only a handful of new treatments** with the potential to address these serious threats are currently in development.³

[†] At least one of the approved drugs and the drug that has completed phase 3 and had its new drug application submitted to FDA have the potential to treat Gram-negative ESKAPE pathogens.

Critical threat pathogens

The World Health Organization considers three bacteria—all of which are resistant to last-line carbapenem antibiotics—to be critical threats to public health. These pathogens—carbapenem-resistant Enterobacteriaceae (CRE), *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*⁴—often cause severe complications in hospitalized patients, with up to 50 percent of patients dying from bloodstream infections caused by CRE.⁵ There is an urgent need to address these critical threats, but only 12 antibiotics in development have the potential to treat infections caused by these bacteria.



Only 12 antibiotics in development have the potential to treat WHO's critical threat pathogens.



Endnotes

- 1 Michael Hay et al., "Clinical Development Success Rates for Investigational Drugs," *Nature Biotechnology* 32 (2014): 40-51, <http://dx.doi.org/10.1038/nbt.2786>. For more information on clinical trial phases, please see the glossary of terms at <http://www.pewtrusts.org/en/research-and-analysis/analysis/2014/03/12/glossary-for-the-antibiotic-pipeline>.
- 2 The ESKAPE pathogens—*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species—cause many infections in the United States and show resistance to many currently available antibiotics. Within the ESKAPE pathogens are key Gram-negative bacteria, including *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *Enterobacter* species. These pathogens are particularly concerning due to the difficulty in discovering new therapies that can overcome current resistance. Stakeholders often highlight the Gram-negative ESKAPE pathogens as an area in which drug innovation is urgently needed.
- 3 An antibiotic is considered to have potential to treat resistant Gram-negative ESKAPE pathogens if the drug has in vitro data showing both activity against one or more Gram-negative species that are considered ESKAPE pathogens and the potential for clinically significant improved coverage of resistant isolates of these species relative to currently available antibiotics. For additional information, please see <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development>.
- 4 World Health Organization, "Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics" (2017), <http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/>.
- 5 U.S. Centers for Disease Control and Prevention, "Antibiotic Resistance Threats in the United States, 2013" (2013), <https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>.

This infographic is based on analysis as of September 2017.

For further information, please visit:

pewtrusts.org/antibiotic-pipeline

Contact: Katie Portnoy, senior associate **Email:** kportnoy@pewtrusts.org **Phone:** 202-540-6483

The Pew Charitable Trusts is driven by the power of knowledge to solve today's most challenging problems. Pew applies a rigorous, analytical approach to improve public policy, inform the public, and invigorate civic life.